PH31649A - Process for the production of TGF beta. - Google Patents

Process for the production of TGF beta.

Info

Publication number: PH31649A
Authority: PH; Philippines
Prior art keywords: production; beta; tgf; tgf beta; pharmaceutical compositions
Prior art date: 1989-12-06

Application number

PH8001A

Other languages

English (en)

Inventor

Cerletti Nico

Kentmcmaster Gary

Cox David

Schmitz Albert

Meyhack Bernd

Original Assignee

Ciba Geigy Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-12-06

Filing date

1994-03-25

Publication date

1999-01-12

1994-03-25 Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag

1999-01-12 Publication of PH31649A publication Critical patent/PH31649A/en

Links

ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title abstract 4
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Immunology (AREA)
Zoology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Gastroenterology & Hepatology (AREA)
Analytical Chemistry (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Toxicology (AREA)
Crystallography & Structural Chemistry (AREA)
Pain & Pain Management (AREA)
Physics & Mathematics (AREA)
Transplantation (AREA)
Dermatology (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Rheumatology (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)

PH8001A 1989-12-06 1994-03-25 Process for the production of TGF beta. PH31649A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB898927546A GB8927546D0 (en)	1989-12-06	1989-12-06	Process for the production of biologically active tgf-beta

Publications (1)

Publication Number	Publication Date
PH31649A true PH31649A (en)	1999-01-12

Family

ID=10667491

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PH8001A PH31649A (en)	1989-12-06	1994-03-25	Process for the production of TGF beta.

Country Status (23)

Country	Link
US (2)	US5650494A (de)
EP (2)	EP0891985A1 (de)
JP (1)	JP3048061B2 (de)
KR (1)	KR100203230B1 (de)
AT (1)	ATE178616T1 (de)
AU (1)	AU638075B2 (de)
CA (1)	CA2031430C (de)
DE (1)	DE69033040T2 (de)
DK (1)	DK0433225T3 (de)
ES (1)	ES2132066T3 (de)
FI (1)	FI103278B1 (de)
GB (1)	GB8927546D0 (de)
GR (1)	GR3030703T3 (de)
HU (1)	HU218144B (de)
IE (2)	IE990992A1 (de)
IL (1)	IL96549A (de)
MX (1)	MX172600B (de)
NO (1)	NO301768B1 (de)
NZ (1)	NZ236333A (de)
PH (1)	PH31649A (de)
PT (1)	PT96068B (de)
SG (1)	SG52690A1 (de)
ZA (1)	ZA909762B (de)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6150328A (en)	1986-07-01	2000-11-21	Genetics Institute, Inc.	BMP products
GB8927546D0 (en) *	1989-12-06	1990-02-07	Ciba Geigy	Process for the production of biologically active tgf-beta
ES2119779T3 (es) *	1990-09-05	1998-10-16	Southern Cross Biotech Pty Ltd	Solubilizacion de proteinas en formas activas.
GB9106678D0 (en) *	1991-03-28	1991-05-15	Ferguson Mark W J	Wound healing
DE69233022T2 (de) *	1991-11-04	2004-02-12	Genetics Institute, LLC, Cambridge	Rekombinante knochenmorphogenetische protein heterodimere, zusammensetzungen und verfahren zur verwendung
US20080139474A1 (en) *	1991-11-04	2008-06-12	David Israel	Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
AU2738392A (en) *	1991-11-11	1993-05-13	Ciba-Geigy Ag	Novel hybrid transforming growth factors
US5288931A (en) *	1991-12-06	1994-02-22	Genentech, Inc.	Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
HU218845B (hu) *	1992-02-12	2000-12-28	Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh.	Új növekedési/differenciáló faktorokat kódoló DNS-szekvenciák, e faktorokat tartalmazó gyógyszerkészítmények, DNS-molekulák, gazdaszervezetek, antitestek, diagnosztikai eljárások
GB9206861D0 (en)	1992-03-28	1992-05-13	Univ Manchester	Wound healing and treatment of fibrotic disorders
US6884787B2 (en) *	2001-07-14	2005-04-26	Isis Pharmaceuticals, Inc.	Antisense modulation of transforming growth factor-beta 3 expression
DE4243729A1 (de) *	1992-12-23	1994-06-30	Behringwerke Ag	Verfahren zur Reaktivierung von gereinigten Membranproteinen
WO1994015968A1 (en) *	1993-01-08	1994-07-21	The Upjohn Company	Process for the purification and refolding of human respiratory syncytial virus fg glycoprotein
US6455689B1 (en) *	1993-04-30	2002-09-24	Biognostik Gesellschaft für Biomolekulare Diagnostik mbH	Antisense-oligonucleotides for transforming growth factor-β (TGF-β)
US5663304A (en) *	1993-08-20	1997-09-02	Genentech, Inc.	Refolding of misfolded insulin-like growth factor-I
US6291206B1 (en)	1993-09-17	2001-09-18	Genetics Institute, Inc.	BMP receptor proteins
US5411940A (en) *	1993-09-29	1995-05-02	Alcon Laboratories, Inc.	Use of TGF-β3 to reduce the formation of scar tissue in response to corneal trauma
EP0670733A1 (de) *	1993-09-29	1995-09-13	Alcon Laboratories, Inc.	Zusammensetzungen welche wachstumsfaktoren und antineoplastische mitteln enthalten
DE69434651T2 (de)	1993-12-07	2007-03-08	Genetics Institute, Inc., Cambridge	Bmp-12, bmp-13 und diese enthaltende sehne-induzierende zusammensetzungen
US5399677A (en) *	1993-12-07	1995-03-21	Genetics Institute, Inc.	Mutants of bone morphogenetic proteins
US6027919A (en)	1993-12-07	2000-02-22	Genetics Institute, Inc.	BMP-12 and BMP-13 proteins and DNA encoding them
TW517059B (en) *	1994-07-25	2003-01-11	Ciba Geigy Ag	New process for the production of biologically active protein
FI970230L (fi) *	1994-07-25	1997-01-20	Ciba Geigy Ag	Menetelmä proteiinien, kuten yhdistelmä-DNA-hirudiinin tai -epidermaalisen kasvutekijän laskostamiseksi
TW440566B (en) *	1994-07-25	2001-06-16	Novartis Ag	Novel process for the production of biologically active dimeric protein
US7235527B2 (en) *	1995-04-19	2007-06-26	Biopharm Gesellschaft Zur Biotechnologieschen Entwicklung Von Pharmaka Mbh	Protein and process for producing the same
US5714371A (en) *	1995-05-12	1998-02-03	Schering Corporation	Method for refolding insoluble aggregates of hepatitis C virus protease
US5800811A (en) *	1995-06-06	1998-09-01	Hall; Frederick L.	Artificial skin prepared from coclagen matrix containing transforming growth factor-β having a collagen binding site
US6352972B1 (en) *	1995-06-06	2002-03-05	Marcel E. Nimni	Bone morphogenetic proteins and their use in bone growth
US6040431A (en) *	1995-06-07	2000-03-21	Stryker Corporation	Single chain analogs of the TGF-β superfamily (morphons)
CA2235223A1 (en)	1995-10-30	1997-05-09	Massachusetts Institute Of Technology	Rationally designed polysaccharide lyases derived from heparinase i
JP4019432B2 (ja) *	1995-12-21	2007-12-12	味の素株式会社	ヒトアクチビンａのリフォールディング方法
US20030185792A1 (en) *	1996-01-22	2003-10-02	Curis, Inc.	Morphogen analogs of bone morphogenic proteins
CA2244228A1 (en) *	1996-01-22	1997-07-24	Creative Biomolecules, Inc.	Morphogen analogs and methods for producing them
US6664227B1 (en)	1996-03-01	2003-12-16	Genetics Institute, Llc	Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
US7811793B2 (en)	1996-12-25	2010-10-12	Biopharma Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh	Process for preparing purified active monomer of bone-derived factor
US7723473B2 (en)	1997-06-19	2010-05-25	St. Louis University	Peptide antagonists of TGF-beta family members and therapeutic uses thereof
US6500920B1 (en) *	1997-06-19	2002-12-31	St. Louis University	Inhibitor of transforming growth factor β and A method of inhibiting the biological effects of transforming growth factor
EP0896825B1 (de)	1997-08-14	2002-07-17	Sulzer Innotec Ag	Zusammensetzung und Vorrichtung zur Reparatur von Knorpelgewebe in vivo bestehend aus Nanokapseln mit osteoinduktiven und/oder chondroinduktiven Faktoren
US20020052026A1 (en)	1997-10-08	2002-05-02	Steven M. Vicik	Methods of refolding proteins
DE19749259A1 (de) *	1997-11-07	1999-05-12	Dade Behring Marburg Gmbh	Verfahren zur Herstellung von funktionalem rekombinantem Gewebsfaktor
ATE513042T1 (de) *	1998-02-05	2011-07-15	Glaxosmithkline Biolog Sa	Tumorassoziierte antigenderivate der mage-familie,nukleinsäuresequenzen, die dafür kodieren, zur herstellung von fusionsproteinen und zusammensetzungen zur impfung
US6057128A (en)	1998-03-17	2000-05-02	Genetics Institute, Inc.	MU-1, member of the cytokine receptor family
FR2776521B1 (fr) *	1998-03-27	2000-12-15	Pf Medicament	Utilisation de conjugues p40 actifs par voie nasale
EP1109919A2 (de)	1998-08-27	2001-06-27	Massachusetts Institute Of Technology	Von heparinase i und ii abgeleitete heparinasen
US7056504B1 (en)	1998-08-27	2006-06-06	Massachusetts Institute Of Technology	Rationally designed heparinases derived from heparinase I and II
US6933272B1 (en)	1998-09-22	2005-08-23	Erik Helmerhorst	Use of non-peptidyl compounds for the treatment of insulin related ailments
US6677432B1 (en)	1998-10-07	2004-01-13	Stryker Corporation	Mutations of the C-terminal portion of TGF-β superfamily proteins
US6846906B1 (en)	1998-10-07	2005-01-25	Stryker Corporation	Modified proteins of the TGF-β superfamily, including morphogenic proteins
AU1103900A (en) *	1998-10-07	2000-04-26	Stryker Corporation	Modified tgf-beta superfamily proteins
US7087577B2 (en)	1998-10-16	2006-08-08	Zimmer Orthobiologies, Inc.	Method of promoting natural bypass
US6992066B2 (en)	1998-10-16	2006-01-31	Zimmer Orthobiologics, Inc.	Povidone-containing carriers for polypeptide growth factors
ES2146552B1 (es) *	1998-11-24	2001-04-16	Inst Cientifico Tecnol Navarra	Peptidos inhibidores de tgf/31
EP1142908A4 (de) *	1999-01-07	2002-05-22	Takeda Chemical Industries Ltd	Methode zum herstellen von aktivierten proteinen
US6727224B1 (en)	1999-02-01	2004-04-27	Genetics Institute, Llc.	Methods and compositions for healing and repair of articular cartilage
DE19906096A1 (de)	1999-02-13	2000-08-17	Walter Sebald	Protein mit einem Heparin-bindenden Epitop
JP4824170B2 (ja)	1999-04-23	2011-11-30	マサチューセッツインスティテュートオブテクノロジー	ポリマーを表記するためのシステムおよび方法
DE19944626A1 (de) *	1999-09-17	2001-03-22	Knoell Hans Forschung Ev	Verfahren zur Herstellung von dimeren, biologisch aktiven knochenmorphogenetischen Proteinen
ATE271886T1 (de)	1999-10-15	2004-08-15	Inst Genetics Llc	Hyaluronsäure enthaltende zusammensetzungen zur abgabe osteogener proteine
WO2001066772A2 (en)	2000-03-08	2001-09-13	Massachusetts Institute Of Technology	Heparinase iii and uses thereof
DE10026713A1 (de) *	2000-05-30	2001-12-06	Walter Sebald	Mutein einer Kette eines Proteins aus der Superfamilie des Wachstumsfaktors TGF-beta
US7081240B1 (en) *	2000-06-28	2006-07-25	Zimmer Orthobiologics, Inc.	Protein mixtures for wound healing
DE60138115D1 (de)	2000-09-12	2009-05-07	Massachusetts Inst Technology	Verfahren und produkte, die mit niedermolekularem heparin assoziiert sind
US7709461B2 (en)	2000-10-18	2010-05-04	Massachusetts Institute Of Technology	Methods and products related to pulmonary delivery of polysaccharides
US7442370B2 (en)	2001-02-01	2008-10-28	Biogen Idec Ma Inc.	Polymer conjugates of mutated neublastin
ES2370235T3 (es)	2001-02-23	2011-12-13	Immunex Corporation	Recuperación eficaz de proteínas replegadas correctamente.
US7276580B2 (en)	2001-03-12	2007-10-02	Biogen Idec Ma Inc.	Neurotrophic factors
WO2002099037A2 (en)	2001-06-01	2002-12-12	Wyeth	Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins
TWI267378B (en)	2001-06-08	2006-12-01	Wyeth Corp	Calcium phosphate delivery vehicles for osteoinductive proteins
FI117667B (fi)	2001-07-05	2007-01-15	Univ Zuerich	Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
ES2629395T3 (es)	2001-10-04	2017-08-09	Genetics Institute, Llc	Métodos y composiciones para modular la actividad de la interleucina-21
US7232802B2 (en)	2001-12-21	2007-06-19	Zimmer Orthobiologics, Inc.	Compositions and methods for promoting myocardial and peripheral angiogenesis
RU2295535C2 (ru) *	2002-02-05	2007-03-20	Джимонат С.П.А.	Рекомбинантный плацентарный фактор роста и способ его получения
EP1472286B1 (de) *	2002-02-05	2007-04-04	GEYMONAT S.p.A.	Verfahren zur rekombinanten herstellung von plazenta wachstumsfaktor
US7622562B2 (en)	2002-06-26	2009-11-24	Zimmer Orthobiologics, Inc.	Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue
JP2006508049A (ja) *	2002-08-13	2006-03-09	ワイエス	増殖因子βタンパク質を形質転換するための可溶化賦形剤としてのペプチド
JP4571776B2 (ja) *	2002-11-05	2010-10-27	Ｊｘ日鉱日石エネルギー株式会社	潤滑油組成物
US7074412B2 (en)	2003-01-30	2006-07-11	The University Of Zurich	Pharmaceutical composition
WO2004094592A2 (en)	2003-04-18	2004-11-04	Biogen Idec Ma Inc.	Polymer-conjugated glycosylated neublastin
DE602004005477T2 (de)	2003-09-12	2007-12-13	Wyeth	Injizierbare feste Calciumphosphat-Stäbe zur Abgabe von osteogenen Proteinen
EP2335650B1 (de)	2003-12-11	2012-10-03	Isto Technologies Inc.	Teilchenförmiges Knorpelsystem
KR101215697B1 (ko) *	2004-08-19	2012-12-28	바이오겐 아이덱 엠에이 인코포레이티드	뉴블라스틴 변형체
KR101241551B1 (ko) *	2004-08-19	2013-03-11	바이오겐 아이덱 엠에이 인코포레이티드	전환 성장 인자 베타 패밀리 단백질의 리폴딩
US20060166251A1 (en) *	2005-01-26	2006-07-27	Archambault Joanne M	Use of sFRPs as markers of BMP activity
EP2322553A3 (de)	2005-02-14	2011-11-16	Wyeth LLC	Interleukin-17FAntikörper und andere Antagonisten der IL-17F Signalübertragung sowie deren Verwendungen
CN101160528A (zh)	2005-02-14	2008-04-09	惠氏公司	Il17-f在诊断和治疗气道炎症中的用途
EP1863518A2 (de) *	2005-03-30	2007-12-12	Wyeth	VERFAHREN ZUR STIMULATION DES WAARWACHSTUMS MITTELS VERABREICHUNG VON BMPs
GT200600148A (es)	2005-04-14	2006-11-22		Metodos para el tratamiento y la prevencion de fibrosis
GB0514262D0 (en) *	2005-07-12	2005-08-17	Renovo Ltd	Promotion of epithelial regeneration
AU2006272714A1 (en) *	2005-07-25	2007-02-01	Trubion Pharmaceuticals, Inc.	Compositions and methods for protein deaggregation
GB0516204D0 (en) *	2005-08-06	2005-09-14	Riotech Pharmaceuticals Ltd	Methods
WO2007025290A2 (en)	2005-08-26	2007-03-01	Isto Technologies, Inc.	Implants and methods for repair, replacement and treatment of joint disease
TWI501774B (zh)	2006-02-27	2015-10-01	Biogen Idec Inc	神經性病症之治療
US7582609B2 (en) *	2006-03-01	2009-09-01	Digna Biotech, S.L.	Method for the treatment of skin fibrosis and suitable compositions for such treatment
ES2450065T3 (es) *	2006-03-01	2014-03-21	Biogen Idec Ma Inc.	Composiciones y métodos para la administración de proteínas de la familia de ligandos del GDNF
GB0604966D0 (en) *	2006-03-11	2006-04-19	Renovo Ltd	Medicaments and proteins
GB0604964D0 (en) *	2006-03-11	2006-04-19	Renovo Ltd	Protein folding
GB0604938D0 (en)	2006-03-11	2006-04-19	Renovo Ltd	Proteins, nucleic acids and medicaments
SG162834A1 (en) *	2006-07-14	2010-07-29	Genentech Inc	Refolding of recombinant proteins
GB0617816D0 (en) *	2006-09-11	2006-10-18	Renovo Ltd	Nucleic acids and methods of protein expression
CA2668771C (en)	2006-11-08	2016-03-15	Wyeth	Rationally designed media for cell culture
US8163549B2 (en)	2006-12-20	2012-04-24	Zimmer Orthobiologics, Inc.	Method of obtaining viable small tissue particles and use for tissue repair
EP2134297B1 (de)	2007-04-12	2017-03-08	Zimmer, Inc.	Vorrichtung zur gewebereparatur
TW200902708A (en)	2007-04-23	2009-01-16	Wyeth Corp	Methods of protein production using anti-senescence compounds
ES2476253T3 (es)	2007-05-01	2014-07-14	Biogen Idec Ma Inc.	P�ptidos de neublastina para su uso en el aumento de la vascularizaci�n en tejido con flujo sanguíneo deteriorado
WO2009020964A2 (en) *	2007-08-08	2009-02-12	Biogen Idec Ma Inc.	Anti-neublastin antibodies and uses thereof
EP2188371B1 (de)	2007-08-09	2017-12-20	Wyeth LLC	Verwendung von perfusion zur erhöhung der produktion von fed-batch-zellkulturen in bioreaktoren
CA2699454C (en)	2007-08-27	2012-07-24	Auxagen, Inc.	Methods for inhibiting tgf-.beta.
WO2010033507A1 (en)	2008-09-16	2010-03-25	St. Louis University	Method of enhancing tgf-beta signalling
US8494140B2 (en) *	2008-10-30	2013-07-23	Centurylink Intellectual Property Llc	System and method for voice activated provisioning of telecommunication services
WO2010051360A1 (en)	2008-10-31	2010-05-06	Wyeth Llc	Purification of acidic proteins using ceramic hydroxyapatite chromatography
KR101741859B1 (ko)	2009-06-22	2017-06-15	암젠 인크	화학적으로 조절된 산화환원 상태를 사용한 단백질의 재폴딩
SI3660032T1 (sl)	2009-06-25	2026-02-27	Amgen Inc.	Postopki zajemanja in čiščenja beljakovin, izraženih v nesesalskem sistemu
KR100991203B1 (ko)	2010-05-10	2010-11-01	심영복	골형성 단백질의 정제 방법
WO2012029148A1 (ja)	2010-09-01	2012-03-08	株式会社オステオファーマ	組換えヒト骨形成タンパク質－２凍結乾燥製剤
KR20180128097A (ko) *	2012-02-10	2018-11-30	재패닉 코포레이션	비 인간 줄기세포의 배양 상등액을 원료로 하는 화장품 또는 피부 재생 촉진제, 및 단백질의 이온 도입 방법
DK2879691T3 (da)	2012-08-06	2019-06-11	Biogen Ma Inc	Fremgangsmåder og sammensætninger til inaktivering af kappebærende vira
US20140178343A1 (en)	2012-12-21	2014-06-26	Jian Q. Yao	Supports and methods for promoting integration of cartilage tissue explants
US9758786B2 (en)	2016-02-09	2017-09-12	Autotelic, Llc	Compositions and methods for treating pancreatic cancer
WO2018122794A1 (en)	2016-12-30	2018-07-05	Biogend Therapeutics Co., Ltd.	Recombinant polypeptides and nucleic acid molecules, compositions, and methods of making and uses thereof
KR20240064367A (ko) *	2022-11-04	2024-05-13	주식회사 대웅제약	TGF-β3 단백질의 정제방법

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
YU76981A (en) *	1980-03-27	1983-09-30	Lilly Co Eli	Process for bonding the a-chain of insulin or insulin analogues and the b-chain of insulin or insulin analogues in order to obtain insulin or insulin analogues
US4620948A (en) *	1982-12-22	1986-11-04	Genentech, Inc.	Purification and activity assurance of precipitated heterologous proteins
GR79124B (de) *	1982-12-22	1984-10-02	Genentech Inc
CA1230591A (en) *	1983-06-03	1987-12-22	Charles A. Frolik	PURIFIED TRANSFORMING GROWTH FACTOR-.beta. DERIVED FROM HUMAN PLATELETS AND PLACENTAS
EP0154434B1 (de) *	1984-02-17	1993-01-27	Genentech, Inc.	Menschlicher Transformationswachstumsfaktor und Vorläufer oder Fragment hiervon, Zellen, DNA, Vektoren und Verfahren zu ihrer Herstellung, Zusammensetzungen und Produkte, die diese enthalten, sowie davon abgeleitete Antikörper und Diagnostizierverfahren
US4572798A (en) *	1984-12-06	1986-02-25	Cetus Corporation	Method for promoting disulfide bond formation in recombinant proteins
US4731440A (en) *	1985-02-22	1988-03-15	Monsanto Company	Method of somatotropin solubilization using dimethylsulfone and naturation
IL78197A (en) *	1985-03-22	1991-07-18	Genentech Inc	Nucleic acid encoding tgf-beta and its uses
GB8508340D0 (en) *	1985-03-29	1985-05-09	Creighton T E	Production of protein
EP0208539A3 (de) *	1985-07-11	1988-08-03	Repligen Corporation	In Falten gelegte Proteine, durch Disulfid gebunden
US5453363A (en) *	1985-10-23	1995-09-26	Boehringer Mannheim Gmbh	Process for the activation of t-PA or Ing after genetic expression in prokaryotes
NZ222168A (en) *	1986-10-20	1991-05-28	Oncogene Science Inc	Tumour growth inhibiting protein related to tgf-#b#1 and tgf-#b#2, preparation by genetic engineering methods, antibodies and pharmaceutical compositions
EP0268561A3 (de) *	1986-11-17	1988-10-26	Sandoz Ag	Herstellung und Verwendung eines T-Zellen-Suppressorfaktors
FI100106B (fi) *	1986-12-05	1997-09-30	Novartis Ag	Menetelmä plasminogeenin yksisäikeisen yhdistelmäaktivaattorin valmist amiseksi
US4931548A (en) *	1987-01-30	1990-06-05	Techne Corporation	Heterodimer form of transforming growth factor-beta
US5013653A (en) *	1987-03-20	1991-05-07	Creative Biomolecules, Inc.	Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
IL86090A (en) *	1987-04-16	1993-03-15	Cetus Oncology Corp	Production of purified, biologically active, bacterially produced recombinant human csf-1
AU622860B2 (en) *	1987-05-11	1992-04-30	Novartis Vaccines And Diagnostics, Inc.	Process for recovering purified, oxidized, renatured recombinant interleukin-2 from microorganisms
US5162507A (en) *	1987-05-11	1992-11-10	Cetus Corporation	Process for recovering purified, oxidized, renatured recombinant interleukin-2 from microorganisms
AU626524B2 (en) *	1987-05-29	1992-08-06	Bristol-Myers Squibb Company	Cloning and expression of simian transforming growth factor- beta 1
US4985544A (en) *	1987-08-04	1991-01-15	Kyowa Hakko Kogyo Co., Ltd.	Process for renaturing fish growth hormone
US5061786A (en) *	1989-05-25	1991-10-29	Genentech, Inc.	Biologically active polypeptides based on transforming growth factor-β
GB8927546D0 (en) *	1989-12-06	1990-02-07	Ciba Geigy	Process for the production of biologically active tgf-beta
US5144006A (en) *	1991-06-13	1992-09-01	The Rockefeller University	Oxidative folding of peptide and protein substrates using hydrocarbon sulfoxides
AU2738392A (en) *	1991-11-11	1993-05-13	Ciba-Geigy Ag	Novel hybrid transforming growth factors

1989
- 1989-12-06 GB GB898927546A patent/GB8927546D0/en active Pending
1990
- 1990-11-27 EP EP98113487A patent/EP0891985A1/de not_active Withdrawn
- 1990-11-27 DE DE69033040T patent/DE69033040T2/de not_active Expired - Lifetime
- 1990-11-27 ES ES90810922T patent/ES2132066T3/es not_active Expired - Lifetime
- 1990-11-27 AT AT90810922T patent/ATE178616T1/de not_active IP Right Cessation
- 1990-11-27 AU AU67018/90A patent/AU638075B2/en not_active Expired
- 1990-11-27 EP EP90810922A patent/EP0433225B1/de not_active Expired - Lifetime
- 1990-11-27 DK DK90810922T patent/DK0433225T3/da active
- 1990-11-27 SG SG1996007909A patent/SG52690A1/en unknown
- 1990-11-30 JP JP2330871A patent/JP3048061B2/ja not_active Expired - Lifetime
- 1990-12-03 FI FI905956A patent/FI103278B1/fi active IP Right Grant
- 1990-12-04 MX MX023579A patent/MX172600B/es unknown
- 1990-12-04 PT PT96068A patent/PT96068B/pt not_active IP Right Cessation
- 1990-12-04 CA CA002031430A patent/CA2031430C/en not_active Expired - Lifetime
- 1990-12-04 NZ NZ236333A patent/NZ236333A/en unknown
- 1990-12-05 IL IL9654990A patent/IL96549A/xx not_active IP Right Cessation
- 1990-12-05 IE IE19990992A patent/IE990992A1/en not_active IP Right Cessation
- 1990-12-05 KR KR1019900019881A patent/KR100203230B1/ko not_active Expired - Lifetime
- 1990-12-05 NO NO905264A patent/NO301768B1/no not_active IP Right Cessation
- 1990-12-05 ZA ZA909762A patent/ZA909762B/xx unknown
- 1990-12-05 HU HU084/90A patent/HU218144B/hu unknown
- 1990-12-05 IE IE438690A patent/IE904386A1/en not_active IP Right Cessation
1994
- 1994-03-25 PH PH8001A patent/PH31649A/en unknown
1995
- 1995-06-07 US US08/486,057 patent/US5650494A/en not_active Expired - Lifetime
1997
- 1997-01-24 US US08/789,588 patent/US5922846A/en not_active Expired - Fee Related
1999
- 1999-07-07 GR GR990401786T patent/GR3030703T3/el unknown

Also Published As

Publication number	Publication date
JPH03191791A (ja)	1991-08-21
DE69033040T2 (de)	1999-09-09
FI905956L (fi)	1991-06-07
NO905264D0 (no)	1990-12-05
ZA909762B (en)	1991-08-28
DE69033040D1 (de)	1999-05-12
EP0433225B1 (de)	1999-04-07
AU6701890A (en)	1991-06-13
IL96549A (en)	2000-10-31
SG52690A1 (en)	1998-09-28
MX172600B (es)	1994-01-03
CA2031430A1 (en)	1991-06-07
KR910012240A (ko)	1991-08-07
US5650494A (en)	1997-07-22
US5922846A (en)	1999-07-13
CA2031430C (en)	2003-05-27
AU638075B2 (en)	1993-06-17
FI103278B (fi)	1999-05-31
NZ236333A (en)	1992-03-26
NO905264L (no)	1991-06-07
PT96068A (pt)	1991-09-30
HUT56880A (en)	1991-10-28
NO301768B1 (no)	1997-12-08
KR100203230B1 (ko)	1999-06-15
FI103278B1 (fi)	1999-05-31
IL96549A0 (en)	1991-09-16
IE904386A1 (en)	1991-06-19
GB8927546D0 (en)	1990-02-07
HU218144B (hu)	2000-06-28
JP3048061B2 (ja)	2000-06-05
ATE178616T1 (de)	1999-04-15
ES2132066T3 (es)	1999-08-16
EP0433225A1 (de)	1991-06-19
PT96068B (pt)	1998-02-27
EP0891985A1 (de)	1999-01-20
FI905956A0 (fi)	1990-12-03
DK0433225T3 (da)	1999-10-25
GR3030703T3 (en)	1999-11-30
HU908084D0 (en)	1991-06-28
IE990992A1 (en)	2000-12-13

Publication	Publication Date	Title
GB8927546D0 (en)	1990-02-07	Process for the production of biologically active tgf-beta
ATE103914T1 (de)	1994-04-15	Neue thienylcarbonsaeureester von aminoalkoholen, ihre quaternierungsprodukte sowie die herstellung und verwendung dieser verbindungen.
IL109578A0 (en)	1994-08-26	Nor-bile acid derivatives, processes for their preparation and the use of these compounds as medicaments
HU896762D0 (en)	1990-03-28	Process for preparation of pyrimidine-derivatives and for manufacturing of pharmaceutical compositions containing these compounds
AU562938B2 (en)	1987-06-25	7, 10, 13, 16 docosatetraenoic acid composition
GR3020098T3 (en)	1996-08-31	11-Beta-aryl-4-estrene, method for its production and its use as a medicine
SG33992G (en)	1992-05-22	Binding-inducing composition
IT1222395B (it)	1990-09-05	Composizione farmaceutica per somministrazione intranasale comprendente l'ormone ghrh,un agonista colinergico e/o un sale biliare
ATE240116T1 (de)	2003-05-15	Verwendung von human-beta-interferon zur herstellung von pharmazeutischen zusammensetzungen zur behandlung von chronischer myeloidleukämie
GR3002679T3 (en)	1993-01-25	Dihydropyridinamides, process for their preparation and their use in medicines
GR3007995T3 (de)	1993-08-31
DE68927055D1 (de)	1996-10-02	2',5'-oligoadenylat-derivate zur verwendung als heilmittel
ZA857721B (en)	1986-09-24	Process for treatment of rheumatic diseases
HU9200400D0 (en)	1992-06-29	Cinurenic acid derivatives, process for producing them and pharmaceutical compositions containing them
MY103584A (en)	1993-08-28	8(alpha)-acylaminoergoline, its preparation and pharmaceutical compositions containing it
HUT46693A (en)	1988-11-28	Process for producing dioxabicyclo/3,3,0/oktanon-oxim-ethers and pharmaceutical compositions containing them as active components
HUT50122A (en)	1989-12-28	Process for producing tetrahydropyridine derivatives and pharmaceutical compositions containing them